Methods of preventing toxicity of platinum drugs
Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.
1. A method for reducing oxaliplatin-induced neurotoxicity in a human subject in need thereof comprising
administering oxaliplatin to the subject in need thereof; and
administering to the subject in need thereof an effective dose of a second agent selected from the group consisting of buflomedil, a buflomedil salt, dolutegravir, and a dolutegravir salt, wherein the subject in need thereof has colorectal cancer or liver cancer; wherein the colorectal cancer or liver cancer expresses at least one of Organic Cation Transporter 1 (OCT1) and Organic Cation Transporter 3 (OCT3); and wherein the neurotoxicity is damage to dorsal root ganglia (DRG).
2. The method of claim 1 , wherein the neurotoxicity is peripheral neurotoxicity.
3. The method of claim 1 , wherein the neurotoxicity is damage to a sensory neuron.
4. The method of claim 1 , wherein the neurotoxicity is chronic neurotoxicity.
5. The method of claim 1 , wherein the neurotoxicity occurs after a subject completes treatment with a cumulative dose of the oxaliplatin of at least 500 mg/m 2 .
6. The method of claim 1 , wherein the dose of the second agent is effective to minimize oxaliplatin-induced neurotoxicity in said subject in need thereof.
7. The method of claim 1 , further comprising assessing oxaliplatin-induced neurotoxicity in a subject after administration of the oxaliplatin.
8. The method of claim 1 , wherein the oxaliplatin and the second agent are administered at the same time.
9. The method of claim 1 , wherein the second agent is administered before the oxaliplatin.
10. The method of claim 1 , wherein the second agent is administered after the oxaliplatin.
11. The method of claim 1 , wherein
a) the amount of oxaliplatin administered to the subject during one treatment session is greater than 60 mg/m 2 ;
b) the cumulative amount of oxaliplatin administered to the subject in need thereof over the entire course of treatment is greater than 780 mg/m 2 ; or
c) the oxaliplatin is administered at a greater frequency than every three weeks.
12. The method of claim 1 , wherein the neurotoxicity is Grade 3 peripheral neuropathy or Grade 4 peripheral neuropathy.
13. The method of claim 1 , wherein the second agent is administered enterally, intravenously, intramuscularly, intraperitoneally, orally, or parenterally.
14. A method for reducing cisplatin-induced neurotoxicity in a human subject in need thereof comprising
administering cisplatin to the subject in need thereof; and
administering to the subject in need thereof an effective dose of a second agent selected from the group consisting of buflomedil, a buflomedil salt, dolutegravir, and a dolutegravir salt,
wherein the subject in need thereof has colorectal cancer or liver cancer; wherein the colorectal cancer or liver cancer expresses at least one of Organic Cation Transporter 1 (OCT1) and Organic Cation Transporter 3 (OCT3); and wherein the neurotoxicity is damage to dorsal root ganglia (DRG).
15. The method of claim 1 , wherein the neurotoxicity is Grade 2 or higher peripheral neuropathy.
16. The method of claim 1 , wherein the colorectal cancer or liver cancer expresses OCT1.
17. The method of claim 1 , wherein the colorectal cancer or liver cancer expresses OCT3.
18. The method of claim 1 , wherein the colorectal cancer or liver cancer expresses OCT1 and OCT3.
19. The method of claim 1 , wherein the colorectal cancer or liver cancer does not express OCT2.
20. The method of claim 1 , wherein the neurotoxicity is acute syndrome transient neurotoxicity.
21. The method of claim 1 , wherein the neurotoxicity is chronic peripheral neuropathy.
22. The method of claim 1 , wherein the neurotoxicity is acute syndrome transient peripheral neuropathy.